A Randomized, Open-label, Phase I Study to Assess the Effects of Food and Formulation on the Pharmacokinetics of a Single Dose of Rilzabrutinib (SAR444671 [Formerly PRN1008]) in Healthy Male and Female Participants
Latest Information Update: 12 Jul 2021
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
- Focus Pharmacokinetics
- Sponsors Principia Biopharma; Sanofi
- 07 Jul 2021 Status changed from recruiting to completed.
- 06 May 2021 Status changed from not yet recruiting to recruiting.
- 23 Feb 2021 Planned End Date changed from 24 Jun 2021 to 1 May 2021.